Astrazeneca (AZN)


AZN Share PerformanceMore

52 week high5,520.0 22/06/17
52 week low3,996.0 06/12/16
52 week change -282.0 (-5.45%)
4 week volume55,369,798 31/08/17

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Director/PDMR Shareholding

RNS Number: 8473R AstraZeneca PLC 26 September 2017 26 September 2017 12:00 BST TRANSACTION BY PERSON DISCHARGING MANAGERIAL RESPONSIBILITIES Disclosure under Article 19 of the EU Market Abuse Regulation AstraZeneca PLC (the Company) announces that, on 25 September 2017, an award of the Company's American Depositary Shar...

Neil Woodford's trades in August 2017

After a busy summer for Neil Woodford, David Brenchley reveals what the star fund manager bought and sold last mon...

Be patient with Neil Woodford

Neil Woodford has come in for some criticism after his recent bad patch. Dzmitry Lipski asks whether his three funds ar...

Aspen acquires remaining rights to AZ anaesthetics

AstraZeneca has entered into an agreement for Aspen Global Incorporated to acquire the residual rights to the established ...

Broker Forecast - Liberum Capital issues a broker note on AstraZeneca PLC

Liberum Capital today downgrades its investment rating on AstraZeneca PLC (LON:AZN) to hold (from buy) and raised ...

Aspen acquires remaining rights to AZ anaesthetics

RNS Number: 6960Q AstraZeneca PLC 14 September 2017 14 September 2017 07:00 BST ASTRAZENECA AND ASPEN ENTER AGREEMENT FOR REMAINING RIGHTS TO ANAESTHETIC MEDICINES Agreement builds on 2016 collaboration on commercialisation rights to anaesthetic medicines in markets outside the US AstraZeneca today announced that it ...

Broker Forecast - JP Morgan Cazenove issues a broker note on AstraZeneca PLC

JP Morgan Cazenove today reaffirms its neutral investment rating on AstraZeneca PLC (LON:AZN) and raised its price ta...

Stocks climb higher by the close

A lack of nasty surprises on the geo-political front helped global stocks on Monday. On the London market Petra Diamond...

Latest discussion posts More

  • Re: quiet

    up another 10+%
  • Bydureon Trial Results

    Results from a large-scale Phase 3 clinical trial, EXSCEL, assessing the cardiovascular risk of AstraZeneca's (AZN +0.1%) BYDUREON (exenatide extended-release) in type 2 ...
    Proverbs 26 vs 5
  • Re: Update on clinical trials

    Neil Woodford, will be pleased and those invested in his funds!!
    Hawk Eye32

Users' HoldingsMore

Users who hold Astrazeneca also hold..
RDS 'B'33%

Codes & Symbols